No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

97 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

NCT00045760Phase 4Completed

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

NCT00049777Phase 4Completed2000 enrolled

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

NCT00067730Phase 4Completed7 enrolled

Leukocyte Depletion of Autologous Whole Blood

NCT00176124Phase 4Completed1089 enrolled

Study of the Use of Coated Venous Catheters in the Critically Ill Child

NCT00202813Phase 4Completed500 enrolled

View all 97 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients.

Naseem Anjum, Hussain Yasser, Ahmad Bashir et al. · J Pak Med Assoc · 2011

PMID: 22368896RCT

Pharmacokinetics of ticarcillin-clavulanate in premature infants.

Watt Kevin M, Hornik Christoph P, Balevic Stephen J et al. · Br J Clin Pharmacol · 2019

PMID: 30710387TrialFull text (PMC)

Accumulation of amikacin in synovial fluid after regional limb perfusion of amikacin sulfate alone and in combination with ticarcillin/clavulanate in horses.

Zantingh Alanna J, Schwark Wayne S, Fubini Susan L et al. · Vet Surg · 2014

PMID: 24467593Trial

Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics.

Munckhof Wendy J, Carney John, Neilson Gail et al. · Int J Antimicrob Agents · 2005

PMID: 15878264Trial

Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males.

Clay Patrick G, Graham Maqual R, Lindsey Cameron C et al. · Am J Geriatr Pharmacother · 2004

PMID: 15561650Trial

Cefepime versus ticarcillin and clavulanate potassium and aztreonam for febrile neutropenia therapy in high-dose chemotherapy patients.

Fleming Donald R, Ziegler Craig, Baize Timothy et al. · Am J Clin Oncol · 2003

PMID: 12796602Trial

Ticarcillin-clavulanic acid plus amikacin versus ceftazidime plus amikacin in the empirical treatment of fever in acute leukemia: a prospective randomized trial.

Fanci R, Paci C, Leoni F et al. · J Chemother · 2003

PMID: 12868552Trial

Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma.

Petrilli Antonio Sérgio, Cypriano Monica, Dantas Lenice Silva et al. · Braz J Infect Dis · 2003

PMID: 12959681Trial

Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial.

Graham Donald R, Talan David A, Nichols Ronald L et al. · Clin Infect Dis · 2002

PMID: 12145720Trial

[A trial of using timentin (ticarcillin/clavulanate) in treating abdominal surgical infection].

Gel'fand E B, Karabak V I, Platova E S et al. · Antibiot Khimioter · 2000

PMID: 10768063Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ticarcillin (substance)
SNOMED CT: 372577006
UMLS CUI: C0040193
RxNorm CUI: 10591

Clinical Data

This intervention maps to 7 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.